National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the treatment of the first-line treatment of metastatic squamous non-small cell lung carcinoma.

 

NCPE Assessment Process Complete
Rapid review commissioned 25/02/2019
Rapid review completed 25/03/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with carboplatin and either paclitaxel or nab-P compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.